MOMENTA PHARMACEUTICALS INC
DelistedCIK 1235010fmd_1A9VC4MDS8Z3AFA2WM9FKB6M7WManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Jun 30, 2020, 43 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 117 | 283 | 64 | 35 | 52 | 90 | 110 | 139 | 76 | 24 |
| Research and development | 52 | 65 | 80 | 104 | 106 | 126 | 120 | 149 | 124 | 145 |
| Total operating expenses | 80 | 103 | 124 | 145 | 152 | 174 | 184 | 231 | 257 | 322 |
| Operating income | 36 | 180 | (60) | (110) | (99) | (84) | (75) | (93) | (181) | (298) |
| Interest expense | 0 | 0 | – | – | – | – | – | 0 | 0 | 2 |
| Interest and investment income | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 6 | 9 |
| Other non-operating income (expense) | 1 | 1 | 1 | 1 | 1 | 1 | 54 | 4 | 5 | 8 |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income to common shareholders | 37 | 180 | (59) | (108) | (99) | (83) | (21) | (88) | (176) | (290) |